Jury Finds Illumina Infringed LadaTech DNA Patent

Law360, Los Angeles (February 29, 2012, 9:40 PM EST) -- Illumina Inc.’s DNA sequencing products infringe a LadaTech LLC patent related to genome analysis technology, a Delaware federal jury ruled Tuesday, rejecting Illumina’s claims that the patent is invalid due to anticipation or obviousness.

Tuesday’s ruling handed a clear victory to LadaTech in a long-running fight over allegations that San Diego, Calif.-based biotechnology company Illumina infringed LadaTech's patent — and caused customers to do the same — when it sold DNA sample preparation kits and cluster generation products.

LadaTech filed the suit in the District of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.